Financials data is unavailable for this security.
Cash flow in CADView more
In 2023, cash reserves at Helix Biopharma Corp fell by 2.44m. Cash Flow from Financing totalled 3.09m or -- of revenues. In addition the company used 5.53m for operations while cash used for investing totalled 5.00k.
Cash flow per share | -0.1466 |
---|---|
Price/Cash flow per share | -- |
Book value per share | -0.0079 |
---|---|
Tangible book value per share | -0.0079 |
More ▼
Balance sheet in CADView more
Current ratio | 0.7382 |
---|---|
Quick ratio | -- |
Total debt/total equity | -- |
---|---|
Total debt/total capital | -- |
More ▼